Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

NCT06699849 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease Vaso-occlusive Crisis

Interventions

BIOLOGICAL: CSL889
DRUG: Placebo

Sponsor

CSL Behring